ORLANDO—Lenalidomide maintenance therapy extended times to disease progression among patients whose multiple myeloma had been treated with autologous stem cell transplantation in a phase III study reported at the American Society of Hematology annual meeting (December 3-7, 2010) in Orlando. Philip McCarthy, Director of the Blood and Marrow Transplant Program at Roswell Park Cancer Institute in Buffalo, New York, discusses the clinical implications of his group’s findings with eCancer Radio.
ASH TELEVISION NEWS REPORTS:
For full coverage of the American Society of Hematology’s 2010 Orlando meeting, visit www.eCancerMedicalScience.com for eCancerTV
LISTEN
[audio:https://www.audiomedica.com/podcasting/ecancer/101209PhilipMcCarthyPODCASTLoRes.mp3]
